AGA Medical’s PREMIUM trial
This article was originally published in The Gray Sheet
Executive Summary
Firm initiates enrollment of its PREMIUM randomized trial to evaluate migraine reduction using its Amplatzer patent foramen ovale (PFO) occluder device, announced July 20. AGA expects to enroll 400 patients at up to 35 medical centers in the U.S. NMT similarly intends to focus on headache reduction following disappointing results from its U.K.-based MIST trial that showed the firm's STARflex PFO closure device to be no more effective than placebo in eliminating migraines entirely (1"The Gray Sheet" April 17, 2006, p. 9)...
You may also be interested in...
NMT Medical To Redesign PFO Trial After Problems With MIST I
NMT Medical will redesign its U.S. pivotal trial for the STARflex patent foramen ovale closure device to treat migraine headaches after its UK trial missed its primary endpoint
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.